We continually innovate and are committed to providing our clients with certified, best-in-class technology. We also offer a team of Meaningful Use Advisors, including Certified Meaningful Use Professionals, as well as a number of digital resources, to help answer your Meaningful Use questions.

Flatiron Health OncoEMR® version 2.8 is ONC Health IT 2015 Edition Cures Update compliant (Product Number: 15.04.04.3010.Onco.28.02.1.221221; certified on December 21, 2022). 

OncoEMR® has certified the below functionality against the ONC 2015 Edition Cures Update requirements based on the test methods and tools noted in the parentheticals. Criteria updated to the Cures Act standard are denoted as such.

Criteria:

  • 170.315 (a)(1): Computerized Provider Order Entry (CPOE) – Medications (ONC Test Method; Version 1.1)
  • 170.315 (a)(2): CPOE – Laboratory (ONC Test Method; Version 1.1)
  • 170.315 (a)(3): CPOE – Diagnostic Imaging (ONC Test Method; Version 1.1)
  • 170.315 (a)(4): Drug-Drug, Drug-Allergy Interaction Checks for CPOE (ONC Test Method; Version 1.1)
  • 170.315 (a)(5): Demographics (ONC Test Method; Version 1.5)
  • 170.315 (a)(9): Clinical Decision Support (ONC Test Method; Version 1.3)
  • 170.315 (a)(10): Drug-Formulary and Preferred Drug List Checks (ONC Test Method; Version 1.1)
  • 170.315 (a)(12): Family Health History (ONC Test Method; Version 1.1)
  • 170.315 (a)(13): Patient-Specific Education Resources (ONC Test Method; Version 1.1)
  • 170.315 (a)(14): Implantable Device List (ONC Test Method; Version 1.3)
  • 170.315 (b)(1): Transitions of Care (ONC Test Method; Version 2.3; Edge Testing Tool; Version 2.3.1; Alteration: N/A) – Updated to Cures Act.
  • 170.315 (b)(2): Clinical Information Reconciliation and Incorporation (ONC Test Method; Version 2.3; Edge Testing Tool; Version 2.3.1; Alteration: N/A) – Updated to Cures Act.
  • 170.315 (b)(3): Electronic Prescribing (ONC Test Method; Version 1.1; Electronic Prescribing; Version 1.2.32; Alteration: N/A) – Updated to Cures Act.
  • 170.315 (c)(1): Clinical Quality Measures – Record and Export (ONC Test Method; Version 1.6; Cypress; Version 3.2.3; Alteration: N/A)
  • 170.315 (d)(1): Authentication, Access Control, Authorization (ONC Test Method; Version 1.1)
  • 170.315 (d)(2): Auditable Events and Tamper-Resistance (ONC Test Method; Version 1.3) Updated to Cures Act.
  • 170.315 (d)(3): Audit Report(s) (ONC Test Method; Version 1.3) Updated to Cures Act.
  • 170.315 (d)(4): Amendments (ONC Test Method; Version 1.1)
  • 170.315 (d)(5): Automatic Access Time-out (ONC Test Method; Version 1.1)
  • 170.315 (d)(6): Emergency Access (ONC Test Method; Version 1.1)
  • 170.315 (d)(7): End-User Device Encryption (ONC Test Method; Version 1.1)
  • 170.315 (d)(8): Integrity (ONC Test Method; Version 1.1)
  • 170.315 (d)(9): Trusted Connection (ONC Test Method; Version 1.1)
  • 170.315 (d)(11): Accounting of Disclosures (ONC Test Method; Version 1.1)
  • 170.315 (e)(1): View, Download, and Transmit to 3rd Party (ONC Test Method; Version 1.5; Edge Testing Tool; Version 2.3.1; Test Data Version 1.4; Alteration: N/A) – Updated to Cures Act.
  • 170.315 (e)(2): Secure Messaging (ONC Test Method; Version 1.1)
  • 170.315 (e)(3): Patient Health Information Capture (ONC Test Method; Version 1.1)
  • 170.315 (f)(1): Transmission to Immunization Registries (ONC Test Method; Version 1.1; HIMSS Immunization Integration Program; Version 1.0; HL7v2 Immunization Test Suite; Version 1.8.0; Alteration: N/A)
  • 170.315(f)(4): Transmission to Cancer Registries (ONC Test Method; Version 1.0; HL7 CDA Cancer Registry Reporting Validation Tool; Version 1.0.5; Alteration: N/A) 
  • 170.315 (g)(2): Automated Measure Calculation (ONC Test Method; Version 1.6)
  • 170.315 (g)(3): Safety-Enhanced Design (ONC Test Method; Version 1.1)
  • 170.315 (g)(4): Quality Management System (ONC Test Method; Version 1.0)
  • 170.315 (g)(5): Accessibility-Centered Design (ONC Test Method; Version 1.0)
  • 170.315 (g)(6): Consolidated CDA Creation (ONC Test Method; Version 1.0; Edge Testing Tool; Version 2.3.1; Alteration: N/A) – Updated to Cures Act.
  • 170.315 (g)(7): Application Access – Patient Selection (ONC Test Method; Version 1.1)
  • 170.315 (g)(9): Application Access – All Data Request (ONC Test Method; Version 1.1; Edge Testing Tool; Version 2.3.1; Alteration: N/A) – Updated to Cures Act.
  • 170.315 (g)(10): Standardized API for patient and population services (ONC Test Method; Version: 2.1) – Updated to Cures Act.
  • 170.315 (d)(12): Encrypt Authentication Credentials (ONC Test Method; Version 1.0) New for Cures Act
  • 170.315 (d)(13): Multi-Factor Authentication (ONC Test Method; Version 1.1) New for Cures Act

OncoEMR® has certified the below CQM’s for use of ONC 2015 certified technology.

CQMs:

CMS68V6: Documentation of Current Medications in the Medical Record

See Certificate of Health IT Compliance.

 


 

Flatiron API Documentation

Flatiron API documentation can be found here.

 


 

Real World Testing: 

Under the ONC Health IT Certification Program, Health IT Developers are required to conduct Real World Testing of their Certified Health IT (45 CFR 170.556 and 170.523(i)). Flatiron’s Real World Test Plans indicated how we planned/are planning to conduct real world testing each year. See Flatiron’s RWT Plans below:

 


 

SVAP Disclosures:

Under the ONC Cures Act Final Rule, “Certified Health IT Developers participating in the Certification Program [are allowed] to voluntarily update their Health IT Modules and provide these updates to its customers to use approved newer versions of standards than are adopted in regulation so long as certain conditions are met” (source).   This is known as the Standards Version Advancement Process (SVAP).

Flatiron has elected to participate in the SVAP process, certifying to criteria 170.315 (g)(10): Standardized API for patient and population services using the HL7 US Core Implementation Guide 4.0.0 based on FHIR Version R4.

 


 

OncoEMR® is 2015 Edition Cures Update compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services.

OncoEMR® requires a one-time implementation fee for installation plus annual subscription fees which cover software licenses, customer support, software upgrades and services required to meet Promoting Interoperability objectives and measures. Use of HL7 interfaces in OncoEMR may also require an additional one-time implementation fee and an additional annual subscription fee for maintenance. Data conversions may also require an additional one-time fee depending on the volume of data being converted. We have also partnered with MaxMD to help users deliver electronic referrals, SureScripts for general e-prescribing functionality, and  DrFirst for controlled substance e-prescribing functionality in OncoEMR. Please note that there are additional one-time and/or annual vendor fees associated with the use of these services.

 

Contact Information:
Margaret Runyan
233 Spring Street
New York, NY 10013, US
[email protected]
704-617-8508